Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Futura Medical Plc LSE:FUM London Ordinary Share GB0033278473 ORD 0.2P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  1.00 5.88% 18.00 17.50 18.50 18.00 17.50 17.50 227,846 08:05:24
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -11.1 -4.4 - 44

Futura Medical Share Discussion Threads

Showing 16826 to 16850 of 19225 messages
Chat Pages: Latest  685  684  683  682  681  680  679  678  677  676  675  674  Older
DateSubjectAuthorDiscuss
10/6/2019
16:00
That article reads like scripted PR.
glavey
10/6/2019
15:23
Futura Medical PLC (LON:FUM) saw its shares shoot higher on Monday after ‘house’ broker Liberum Capital highlighted an article published in ‘The Guardian’ newspaper which could spark interest in the group’s main product. In a note to clients, the City broker’s analysts pointed out that over the weekend the newspaper published an in-depth piece on the emerging treatments for erectile dysfunction (ED) with a significant focus on the AIM-listed firm’s MED2005 which is in a P3 study due to read-out by the end of the year. They said: “The article highlights the lack of clinical advances in ED over the past 20 years and the emerging opportunity for products that can address the shortcomings of the PDe-5 inhibitor class (Viagra) with MED2005 appearing to offer convenience and side-effect profile benefits.” The analysts concluded: “This will help to drive interest in what appears to be a very over-looked product in terms of its potential to address a very large market
j777j
10/6/2019
11:39
How many bags do you see here going forward?
j777j
10/6/2019
08:31
Yep, it’s why we are invested for the long term, should bounce nicely off support here, buy with confidence imo but dyor
ny boy
10/6/2019
08:24
Even if Futura only gets 20% of that,a 15% royalty is still $54 million a year.Amazing potential.
j777j
10/6/2019
07:38
 "Within three months of its launch, Viagra had already earned Pfizer $400m, and over the past two decades, it has consistently generated annual sales to the tune of $1.8bn."
j777j
09/6/2019
10:24
From 1989, using patches: hTTps://www.karger.com/Article/Abstract/281528
rrr
09/6/2019
10:23
Interesting how far back this idea goes - this from 1990 uses a paste: hTTps://www.ncbi.nlm.nih.gov/pubmed/2107336?dopt=Abstract
rrr
09/6/2019
09:32
Great article kd, many thanks.
rrr
09/6/2019
07:45
guardian webiste- The race to replace Viagra https://www.theguardian.com/science/2019/jun/09/race-to-replace-viagra-patents-erectile-dysfunction-drug-medical-research-cialis-eroxon
keifer derrin
07/6/2019
13:29
Im still in hear quite heavily and comfortable with it. Trying not to look too often as it will be a bit of a slow burn until later in the year with fee mm shenanagans in between.
ragnarr
07/6/2019
13:20
Buyers back in !!
dickiebird2
07/6/2019
12:20
certainly 'bottom testing' !
mikethebike4
06/6/2019
16:20
Testing the bottom of the up trend channel, if it holds, it should do well from here.
ny boy
06/6/2019
15:25
I expect some dip buying over the next week or so, before a break to new highs
ny boy
06/6/2019
15:11
Everyone sold out ? I guess no long term investors left then lol! (MSYS) is the next big thing imo but dyor!
ny boy
29/5/2019
11:24
Anyone joining the MAIS shareholder action group?
kemche
29/5/2019
10:52
LO selling again Good luck ... placing coming
ayesha4
24/5/2019
12:11
You are not wrong there Global Erectile Dysfunction Drugs Market Will Reach USD 7.10 Billion by 2024: Zion Market Research According to the report, global erectile dysfunction drugs market was valued at approximately USD 4.82 billion in 2017 and is expected to generate revenue of around USD 7.10 billion by end of 2024, growing at a CAGR of around 5.70% between 2018 and 2024.
ragnarr
24/5/2019
10:51
Not surprising when you consider the upside.
j777j
24/5/2019
10:40
some quite hefty buys today - 50k, 100k, 250k - somebody must be taking an interest
mikethebike4
23/5/2019
16:10
Ahead of the rerating one hopes.
j777j
23/5/2019
15:59
That was definately a tree shake!
xippy
23/5/2019
15:04
Buy note out soon?
j777j
23/5/2019
12:41
FrOm the redent preliminary results. "Cash Balance Cash balance at the end of 2018 was £9.16 million (2017: £8.36 million). Cash burn during the year was £5.63 million (2017: £5.02 million) primarily in relation to MED2005 research and development activities. Net funding of £5.48 million was raised in the year, resulting in a net cash inflow of £0.80 million. Futura is fully funded to deliver the top line data from the first Phase 3 study and will manage its funding strategy appropriately to what is expected to be a material inflection point for the Company." The MED2005 clinical trial Protocol states Estimated Primary Completion Date : October 7, 2019 This isn,t the completion of the whole study that will be later in 2020 but at some point after October there will be update data available to know where its going.Reading all the data to date I think it is safe to say that there is a certain confidence in this Trial. So if there were to be another placing (which is perfectly feasable) it wont be until that upodate is available and the share price is far higher. IMO
ragnarr
Chat Pages: Latest  685  684  683  682  681  680  679  678  677  676  675  674  Older
ADVFN Advertorial
Your Recent History
LSE
FUM
Futura Med..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200810 08:33:05